Percutaneous cryoablation for recurrent low grade renal cell carcinoma after failed nephron-sparing surgery - Abstract

INTRODUCTION: Partial nephrectomy has a 3%-4% incidence of local treatment failure.

This study is to present a series of percutaneous cryoablation for locally recurrent renal cell carcinoma after partial nephrectomy.

MATERIALS AND METHODS: Five consecutive patients were referred to our quarternary center's multidisciplinary Small Renal Mass (SRM) Center for assessment after failure of partial nephrectomy. Tumor size and location was noted. CT-guided cryoablation was performed using an argon/helium-based system (Healthtronics, Austin, Texas, USA). Patients were admitted overnight for observation. Patients were followed with serial imaging, laboratory tests and examination at our SRM Center. Tumor size, location, and nephrometry scores were documented for each patient.

RESULTS: Four tumors were endophytic and one was exophytic. The median tumor size was 2.2 cm (1.8 cm-4.0 cm). Nephrometry scores were 8a, 7x, 4p, 6x, 7p, and 6p prior to cryoablation. Median follow up after cryoablation was 32 months (20-39 months). One patient with a 4.0 cm endophytic tumor developed a second recurrence measuring 2.9 cm 13 months following ablation, which was managed successfully with repeat cryoablation with no evidence of disease after an additional 19 months of follow up. Two patients developed self-limited hematuria which was conservatively managed. There were no other complications, and all patients remained at their pretreatment performance status.

CONCLUSIONS: Percutaneous cryoablation appears to be a safe and effective nephron-sparing modality for control of locally recurrent disease following partial nephrectomy. Most recurrent tumors are endophytic. One patient suffered a second local recurrence, which was managed successfully with repeat cryoablation.

Written by:
Morgan MA, Roberts NR, Pino LA, Trabulsi EJ, Brown DB, Gomella LG, Lallas CD.   Are you the author?
Thomas Jefferson University, Philadelphia, Pennsylvania, USA.

Reference: Can J Urol. 2013 Oct;20(5):6933-7.


PubMed Abstract
PMID: 24128832

UroToday.com Renal Cancer Section